Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 9 more

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Specific T- Lymphocytes; Biological
Lead sponsor: Paul Szabolcs; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 53
States / cities: Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more

Conditions: Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
Interventions: DPX-E7 vaccine, Cyclophosphamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions: Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells, Fludarabine, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 3 Months to 12 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more

Conditions: Hepatitis C, Liver Transplantation
Interventions: cyclosporin (Neoral), tacrolimus (Prograf); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 5 more

Conditions: HIV Infections, Lipodystrophy, Wasting Disease
Interventions: Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 25
States / cities: Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more

Conditions: Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
Interventions: ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab; Biological · Drug · Radiation
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Diego, California • Dallas, Texas

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Hepatitis B Infection, Malignant Solid Neoplasm
Interventions: Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate; Other · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 192
States / cities: Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more

Conditions: Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC, SCC - Squamous Cell Carcinoma, SCCHN, Head Neck Cancer, Head and Neck Squamous Cell Cancer, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck, Squamous Cell Head and Neck Carcinoma, Oral Cavity, Oral Cavity Carcinoma
Interventions: VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection); Biological · Drug
Lead sponsor: VLP Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Kidney Transplant, Hepatitis C
Interventions: Direct acting Anti-Viral Therapy using Epclusa or Zepatier; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: Covid19
Interventions: Colchicine 0.6 mg, Naltrexone; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Saint Louis Park, Minnesota • Saint Paul, Minnesota

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: HIV Infections
Interventions: Amprenavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 8 more

Search by objective public record fields.

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Anti-viral T-cell Therapy by Gamma Capture

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Impact of Colchicine and Low-dose Naltrexone on COVID-19

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients